|
Online CME Activity
Does Amrubicin have a Role as a Second-line Therapy for Platinum Refractory Small-cell Lung Cancer?
|
NOTE: Although this activity is no longer certified for credit, we believe that it contains important information and hope you’ll review, print or email it to a colleague.
Does Amrubicin have a Role as a Second-line Therapy for Platinum Refractory Small-cell Lung Cancer?
1.00 AMA PRA Category 1 Credits™
Learning Objectives
Identify patients with refractory small-cell lung cancer who will benefit from second-line therapy with amrubicin
Accreditation
This educational program is conceived and credited in accordance with ACCME's Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with pmiCME's Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of pmiCME.
| Credits |
Type |
Accreditation Statement |
Designation Statement |
| 1.00 |
AMA PRA Category 1 Credits™ |
pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. |
pmiCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
Faculty and Editorial Board
Written By:
Bruce E. Johnson, MD, (Read Bio), Professor of Medicine, Harvard Medical School, Director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
Edited By:
Carole Chrvala, PhD
Financial Disclosure Statement(s)
Dr Johnson serves as a consultant and receives patent honoraria from Genzyme. He also is a stakeholder and founder of the KEW Group and receives consulting fees from Chugai Pharmaceuticals.
Carole Chrvala, PhD has no financial relationships to disclose.
Education Partner:
Dana-Farber Cancer Institute
Commercial Support:
Lilly USA, LLC, Bristol-Myers Squibb,Genentech BioOncology and OSI Oncology
Instructions for Obtaining Credit:
Complete this activity. Answer the questions in the attached posttest and evaluation. Click on "claim credit" and follow the instructions to print out the credit certificate.
Computer System Requirements:
Internet Explorer (version 5.5 and above) is the recommended browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A minimum screen resolution setting of 800 x 600 is recommended. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.
Disclaimer
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, M|C Communications, LLC or Dana-Farber Cancer Institute.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
|
|
|